Effectiveness of adjuvant supportive-expressive group therapy for breast cancer.
Xiao Ming QuanZhang ZhangXiao Ying ZhangYing TangJian LiangZhe SunMu Zi LiangYuan Liang YuPublished in: Breast cancer research and treatment (2020)
Adjuvant SEGT cannot significantly prolong 5-year survival in breast cancer, though a longer observation period is warranted according to the marginal survival benefit identified at the end of the follow-up.